1.1.1
When referring someone with suspected renal cell carcinoma (RCC) for initial investigations, follow the recommendations in the section on patient information and support in NICE's guideline on suspected cancer.
People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care.
Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.
Healthcare professionals should follow our general guidelines for people delivering care:
These recommendations are to help healthcare professionals provide information and support to people with suspected or confirmed renal cell carcinoma.
We have also written information for people with suspected or confirmed renal cell carcinoma, their families and the general public.
When referring someone with suspected renal cell carcinoma (RCC) for initial investigations, follow the recommendations in the section on patient information and support in NICE's guideline on suspected cancer.
Healthcare professionals in all settings (including primary care, genetics services and multidisciplinary services) should provide ongoing information and support to people with suspected or confirmed RCC, based on a personalised assessment of what the person needs at different times, in line with:
NICE's guideline on patient experience in adult NHS services, particularly the recommendations on:
NICE's guideline on shared decision making, particularly the recommendations on:
NICE's guideline on people's experience in adult social care services, particularly the recommendations on co-production and enabling people to make decisions.
See also section 3.5 (management communication and shared decision making) in the Getting It Right First Time (GIRFT) guide Urology: Towards better care for patients with kidney cancer.
Offer clinical nurse specialist support in secondary care to people with suspected or confirmed RCC during diagnosis, management and follow-up or palliative care.
The clinical nurse specialist supporting the person with suspected or confirmed RCC should:
act as the key worker to address the person's information and care needs and
give their contact details to the person and
have training and experience in kidney cancer care and
attend multidisciplinary team meetings and
act as a link between the urology and oncology teams and
liaise between secondary and primary care, supporting communication and care coordination.
Give the person with suspected or confirmed RCC the contact details for a cancer care navigator, if available.
Throughout their care, discuss with the person with RCC how they are coping with emotions such as sadness, depression and anxiety, and feeling out of control over the outcome of the disease and treatment. Signpost the person to voluntary or community emotional support services, or refer the person to NHS psychological health support services, if and when appropriate.
See also NICE's guideline on depression in adults with a chronic physical health problem.
Offer support to help people with RCC who currently smoke to stop smoking, in line with NICE's guideline on tobacco.
Discuss involvement in clinical trials and other types of research with people with RCC, including:
where to find information (for example, Be Part of Research, Action Kidney Cancer, Kidney Cancer UK and ISRCTN: The UK's Clinical Study Registry)
opportunities for research involvement in their centre and others
the benefits and risks of entering clinical trials and other studies.
Trusts, health boards and any other relevant healthcare providers should consider conducting annual satisfaction surveys of people with RCC – developed by their uro-oncology multidisciplinary team and people with RCC – and use the results to guide quality improvement programmes.
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on information for healthcare professionals to support people with suspected or confirmed renal cell carcinoma.
Full details of the evidence and the committee's discussion are in evidence review D: information needs.